



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/538,376
				Filing Date	June 13, 2005
				First Named Inventor	Nedjeljko Kujundzic
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	03818/0202984-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/E.P./	AA	US 4,492,688	01-08-1985	Bright	
/E.P./	AB	US 4,474,768	10-02-1984	Bright	
/E.P./	AC	US 4,328,334	05-04-1982	Kobrehel, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/E.P./	BA	WO 97/35590		10-02-1997	Platt		
/E.P./	BB	EP 0 316 128		05-17-1989	Pfizer Inc. (Bright)		
/E.P./	BC	EP 0 132 944		12-30-1986	Pfizer Inc. (Bright)		
/E.P./	BD	BE 892,397		03-08-1982	Marchand		
/E.P./	BE	FR 2 473 525		07-17-1981	Roussel-Uclaf		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/E.P./	CA	Puri, S.K., and Singh, Naresh. 2000. Azithromycin: Antimalarial Profile against Blood- and Sporozoite-Induced Infections in Mice and Monkeys. <i>Experimental Parasitology</i> 94:8-14.		
/E.P./	CB	Sadiq, S.T., et al. 1995. Effects of azithromycin on malarimetric indices in The Gambia. <i>The Lancet</i> 346:881-882.		
/E.P./	CC	Kobrehel, Gabrijela, et al. 1993. 9a,11-Cyclic Carbamates of 15-Membered Azalides. <i>The Journal of Antibiotics</i> 46(8):1239-1245.		
/E.P./	CD	Luger, Peter, and Maier, Roland. 1979. Molecular structure of 9-deoxy-11-deoxy-9-11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-(9S)-erythromycin, a new erythromycin derivative. <i>Journal of Crystal and Molecular Structure</i> 9(6):329-338.		
/E.P./	CE	Egan, Richard S., et al. 1974. Configuration of 9-Imino Derivatives of Erythromycin. <i>J. Org. Chem.</i> 39(17):2492-2494.		
/E.P./	CF	Kurath, P., et al. 1971. Acid Degradation of Erythromycin A and Erythromycin B. <i>Experientia</i> 27(4):362.		
/E.P./	CG	Djokic, Slobodan, and Tamburasev, Zrinka. 1967. Erythromycin Study: 9-amino-3-O-cladinosyl-5-O-desoaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecame-13-olide. <i>Tetrahedron Letters</i> 17:1645-1647.		
/E.P./	CH	McGuire, J.M. et al. 1952. "Ilotycin," A New Antibiotic. <i>Antibiotics and Chemotherapy</i> 11(6): 281-283.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	/Elli Peselev/	Date Considered	05/24/2007
--------------------	----------------	-----------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/538,376
				Filing Date	June 13, 2005
				First Named Inventor	Nedjeljko Kujundzic
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	03818/0202984-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/E.P./	AA	US-6,872,707	03/29/2005	Marusic-Istuk et al.	
/E.P./	AB	US-6,852,702	02/08/2005	Kujundzic et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/E.P./	BA	WO 04/043985	05/27/2004	Kujundzic et al.		
/E.P./	BB	WO 04/043984	05/27/2004	Kujundzic et al.		
/E.P./	BC	WO 02/068438	09/06/2002	Pliva D.D.		
/E.P./	BD	EP 0 657 464	06/14/1995	Pliva Pharm. & Chem. Works (HR)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Elli Peselev/	Date Considered	05/24/2007
-----------------------	----------------	--------------------	------------